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Introduction
Chronic heart failure is common, 1 readily diagnosed, the cause of disabling symptoms, has a poor prognosis, and consumes about 2% of the total health budget in developed countries.
Therapeutic strategies for chronic heart failure are based on the notions of restriction of fluid retention and inhibition of activation of neurohumoral systems, notably the reninangiotensin pathway and the sympathetic system. Guidelines recommend a combination of diuretics, angiotensinconverting enzyme (ACE) inhibitors, and ␤ blockers with or without digoxin as a basis for treatment. 2 Aldosterone inhibitors are often used in patients with more severe heart failure. Results of large clinical trials have shown that although treatment with ACE inhibitors lessens admissions and improves survival, 3 morbidity and mortality remain high. Addition of a ␤ blocker further reduces mortality [4] [5] [6] [7] [8] and has various effects on symptoms. [9] [10] [11] Many mechanisms for the benefits of these drugs have been put forward.
␤ blockers have different pharmacological profiles, for example adrenergic receptor selectivity and the presence of ancillary properties. Metoprolol and bisoprolol have a high specificity for the ␤-1 adrenergic receptor. Carvedilol blocks ␤-1, ␤-2, and ␣-1 adrenergic receptors. 12 Bucindolol did not have a mortality benefit in chronic heart failure. 13 Results of a meta-analysis 14 suggested that carvedilol was associated with a greater increase in left-ventricular ejection fraction than metoprolol. Several other small studies 12, [15] [16] [17] have suggested that carvedilol is more effective than metoprolol in terms of remodelling and central haemodynamics, but the two drugs are similar in their effect on quality of life 10 or peak oxygen consumption. 15, 16 Carvedilol has several other effects that might be advantageous in heart failure. It increases insulin sensitivity whereas metoprolol has the opposite effect. 18 The antioxidant action of carvedilol 19 might improve endothelial dysfunction and prevent apoptosis, mechanisms that could be important in the progression of chronic heart failure. 20 We designed the Carvedilol Or Metoprolol European Trial (COMET) to compare directly the effects of carvedilol and metoprolol on mortality and morbidity in patients with mild to severe chronic heart failure.
Methods
Design COMET was a multicentre, randomised, double-blind, parallel-group trial to compare the effect on mortality and morbidity of carvedilol and metoprolol in patients with chronic heart failure. A detailed description of the study design has been published, including the method of randomisation, monitoring, and follow-up. 21 The study was done in 15 European countries, involving 341 centres, of which 317 contributed at least one patient. During the trial one centre was withdrawn from the study because of irregularities. Recruitment began on Dec 1, 1996 Patients Eligible patients were men or women with symptomatic chronic heart failure (New York Heart Association [NYHA] class II-IV), at least one cardiovascular admission during the previous 2 years, on stable heart failure treatment with ACE inhibitors for at least 4 weeks unless contraindicated, and on treatment with diuretics (у40 mg of frusemide or equivalent) for at least 2 weeks. Digitalis, angiotensin II inhibitors, or other vasodilators could be used at the discretion of the investigators. Left-ventricular ejection fraction had to be 0·35 or lower measured within the previous 3 months by echocardiography or radionuclide ventriculography. If the ejection fraction was not determined, a left-ventricular end diastolic diameter of greater than 6·0 cm and a fractional shortening of less than 20% as measured by echocardiography could qualify patients.
Major exclusion criteria were a recent change of treatment-defined as the introduction of a new class of drug for heart failure or treatment with oral ␤-adrenergic or ␣-adrenergic receptor blockers within the 2 weeks before randomisation-requirement for intravenous inotropic therapy, current treatment with calcium channel blockers (of the diltiazem or verapamil class), amiodarone (>200 mg per day) or class-I antiarrhythmic drugs, or administration of any investigational drug within the preceding 30 days. We excluded patients with unstable angina, myocardial infarction, or coronary revascularisation or stroke within the previous 2 months. Other exclusion criteria were uncontrolled hypertension (blood pressure systolic >170 mm Hg or diastolic >105 mm Hg), haemodynamically significant valvular disease, symptomatic and sustained ventricular arrhythmias within the past 2 months not adequately treated with antiarrhythmic drugs or implantation of an automatic defibrillator, pregnancy, women with childbearing potential on inadequate contraception, known drug or alcohol misuse, poor compliance with treatment or any other serious systemic disease that might complicate management and reduce life expectancy.
We also excluded patients if there was a contraindication to use of ␤ blockers, such as resting heart rate of fewer than 60 beats per min, sick sinus syndrome, bifascicular block, second or third degree atrioventricular block unless treated with a pacemaker, sitting systolic blood pressure of less than 85 mm Hg, history of asthma or chronic obstructive pulmonary disease, peripheral arterial disease with symptoms at rest, or unstable insulin-dependent diabetes mellitus.
The study conformed to good clinical practice guidelines and followed the recommendations of the Declaration of Helsinki. The protocol was approved by the relevant and local ethics review boards. Written informed consent was obtained from all patients before enrolment.
Procedures
At randomisation, we assigned the 3029 eligible patients to receive either 3·125 mg carvedilol twice daily or 5 mg metoprolol tartrate twice daily. Randomisation was double blind and used the method of permuted blocks by centre. Investigators at each sites were supplied with numbered treatment kits and instructed to take the lowest numbered kit available for each new patient. Each kit contained sufficient drugs to allow complete flexibility of treatment. Patients entered initially a titration phase followed by a maintenance period.
During the titration phase the dose of each ␤ blocker was increased to the target dose of carvedilol (25 mg twice daily) or metoprolol (50 mg twice daily) every 2 weeks according to the following schedules: 6·25 mg twice daily, 12·5 mg twice daily, and 25 mg twice daily for carvedilol, and 12·5 mg twice daily, 25 mg twice daily, and 50 mg twice daily for metoprolol. The investigator could modify the dose regimen. If a patient did not tolerate an increase of dose, a temporary decrease in dose was allowed. Investigators were encouraged to adjust the dose of diuretics and ACE inhibitors to increase the dose of the ␤ blocker again towards the target dose. Subsequently during the maintenance phase all patients were assessed every 4 months until the end of the study. Patients undergoing heart transplantation remained in the study and were followed up in a manner identical to other patients.
Safety was monitored by an independent data and safety monitoring board. Adverse and serious adverse events were reported to the study data centre. All reports of adverse events were included irrespective of whether the investigators thought they had been caused by the treatment. Adverse events that were fatal or lifethreatening, required or extended admission, or resulted in persistent or significant disability or incapacity were labelled serious. All adverse events were coded, blinded to treatment group, by a validated and established dictionary that classifies events by major body systems. This procedure identifies cardiovascular events.
All fatal events were adjudicated by the endpoint committee masked to treatment status. We assigned mode of death to one of five categories: sudden death, circulatory failure, stroke, other cardiovascular death, and noncardiovascular death. Deaths that could not be classified because of insufficient information were deemed cardiovascular.
Statistical analysis
The study was planned as an event-driven parallel-group survival study to compare carvedilol and metoprolol with respect to all-cause mortality. In May, 2000, the steering committee, who had no knowledge of the interim results or treatment assignments, decided to add the composite endpoint of all-cause mortality or all-cause admission as a second primary endpoint. This endpoint had previously been the first secondary endpoint specified by the protocol. The change was made in recognition of the importance of admission in this population and to ensure that COMET had primary endpoints identical to those used in the MERIT-HF study. 6 With the introduction of the second primary endpoint, we recalculated the required number of deaths. Although a composite endpoint had been introduced it remained our intention that the study be adequately powered to detect a mortality difference. 1020 fatal events were needed to detect a risk reduction of 20% with at least 80% power. This calculation reflected the following: premature end of study treatment would reduce the anticipated risk reduction in mortality by 20%, aggregate yearly mortality would be 8·1% and the overall type I error of 0·05 would be split-0·04 for all-cause mortality and 0·01 for the composite endpoint. With respect to the composite endpoint, about 2400 events were expected, giving 80% power to detect a 15% reduction in risk at a significance level of 0·01. By the end of 2001, projections indicated that the required number of deaths would occur by November, 2002. The steering committee declared that all patients alive on Nov 15, 2002, would be administratively censored on that date for the purpose of all efficacy analyses. By that date 1112 patients had died.
Throughout the study, the data safety and monitoring board did regular reviews for efficacy and safety. Since use of ␤ blockers for heart failure was quite new at the start of the study, these reviews were scheduled for every 100 deaths. The protocol specified a fixed significance level of 0·0001 (Peto rule   22 ) as a guideline for stopping the study at each interim analysis. However, the study finished as planned without early termination. Formally, the significance level for a comparison of treatments with respect to mortality must be less than 0·039 to ensure that the type I error for the study as a whole remains less than 0·05.
All randomised patients were included in the analysis of both efficacy and safety by the intention-to-treat principle. It was planned that all patients would be followed up to the end of the study, even after study treatment ended permanently. Some patients were lost to follow-up or withdrew consent. These patients were censored at the last known date of contact or date of withdrawal of consent, respectively.
We analysed the primary endpoints with a log-rank test without stratification. The relative risk (hazard ratio) and 95% CI were estimated with a Cox's proportional hazard model with treatment as the only covariate. Sensitivity analyses to assess the robustness of the primary endpoint results accounted for the effect of additional baseline covariates and used a survival analysis with time-dependent covariates to assess the relative contribution of study treatments and any use of open-label ␤ blockade after previous end of study drugs.
Recorded survival times were well described by a statistical model that assumed a constant hazard in each treatment group (exponential survival). On this basis, standard maximum likelihood methods were used to obtain an estimate and a CI for the difference in median survival between the treatments.
Role of the funding source
The trial was designed, overseen, implemented, and assessed by an independent steering committee. Representatives of the sponsor attended meetings of the steering committee as non-voting members and in addition the independent members met separately. The study database is held by an independent data centre, the Nottingham Clinical Research Group, Nottingham, UK. The data centre was also responsible for statistical analysis of the data. Day to day operations were managed initially by Boehringer Mannheim and later by F Hoffmann La Roche.
Results
Of 3029 patients, 1511 (50%) were assigned to treatment with carvedilol and 1518 (50%) to metoprolol (figure 1). The mean study duration was 58 months (SD 6). Five patients were lost to follow-up and a further 28 patients withdrew their consent to further follow-up during the course of the study. All other patients were followed up to death or study end. Table 1 shows the baseline characteristics. The mean age was 62 years (11) and the mean ejection fraction 0·26 (0·07). Patients were evenly distributed between NYHA II and III. Figure 2 shows the Kaplan-Meier estimates of all-cause mortality for each treatment. 512 people in the carvedilol group died compared with 600 in the metoprolol group, giving a hazard ratio of 0·83 (95% CI 0·74-0·93, p=0·0017) in favour of carvedilol. The mortality benefit became apparent at about 6 months. The reduction in all-cause mortality was similar in direction and in magnitude across the predefined subgroups ( figure 3 ). In addition, sensitivity analyses confirmed the primary mortality analysis. The difference remained after adjustment for known prognostic factors. The ontreatment analysis showed a hazard ratio of 0·77 (0·67-0·90, p=0·0008) in favour of the carvedilol group. Although the number of deaths differed between groups, the distribution of mode of death was much the same for the two treatments. Sudden death was the adjudicated mode of death for 218 patients (14%) in the carvedilol group and in 262 (17%) patients in the metoprolol group-43% of all deaths in the carvedilol group and 44% in the metoprolol group. 33% of all deaths in both groups (n=168 for carvedilol and n=197 for metoprolol) were due to circulatory failure.
There were 438 cardiovascular deaths in the carvedilol group and 534 in the metoprololol group (table 2) . 28 patients in the carvedilol group and 27 in the metoprolol group underwent heart transplantation.
1116 patients in the carvedilol group and 1160 in the metoprolol group died or were admitted ( hazard ratio for total admission alone was 0·97 (95% CI 0·89-1·05, p=0·45) so that the composite endpoint was driven mainly by mortality. The mean daily dose at entry into the maintenance phase in the carvedilol group (n=1308) was 41·8 mg (SD 14·6) a day, with 1140 (87%) patients taking 25 mg a day or more, and 980 (75%) receiving the target dose of 25 mg twice a day. In the metoprolol group (n=1317) the mean daily dose was 85 mg a day (SD 28·9), 1146 (87%) taking 50 mg a day or more, and 1019 (78%) receiving the target dose of 50 mg twice a day.
The mean baseline heart rates were identical (table 1) . After 4 months of treatment, mean heart rate on treatment had decreased from baseline by 13·3 beats per min in the carvedilol group and by 11·7 beats per min in the metoprolol group (difference -1·6 beats per min, 95% CI -2·7 to -0·6). The change in heart rate for all patients over the period of the trial is shown in figure 4 . The heart rate did not differ after 16 months. At 4 months, patients mean decrease of systolic blood pressure from baseline was 3·8 mm Hg (SD 17·4) in the carvedilol group and 2·0 mm Hg (SD 17·7) in the metoprolol group (difference -1·8 mm Hg, 95% CI -3·2 to -0·4).
The study drug was permanently stopped for reasons other than death in 481 (32%) patients in the carvedilol group and in 483 (32%) in the metoprolol group. Reasons for permanent cessation of treatment were similar in the two groups, as were the distributions of time on treatment. In the carvedilol group 80·5% of the survival time was spent on the study drug, compared with 81·5% in the metoprolol group. The proportion of patients who had adverse events or serious adverse events and the number of events were fewer in the carvedilol group than the metoprolol group despite differences in mortality leading to a slightly longer mean observation time of 46·8 months (SD 18·9) compared with 45·2 months (19·5) for metoprolol (tables 2 and 3). The pattern of adverse events usually associated with ␤ blockade was similar in the two groups. Bradycardia was reported in 144 (10%) patients in the carvedilol group and in 135 (9%) patients in the metoprolol group. Bradycardia was a serious adverse event in 3% of patients in both groups (n=39 with carvedilol and n=40 with metoprolol). Hypotension was reported in 215 (14%) patients in the carvedilol group and in 160 (11%) patients in the metoprolol group. Hypotension was a serious adverse event in 48 (3%) and in 29 (2%) of patients, respectively.
Discussion
Our results suggest that carvedilol used for treatment of chronic heart failure, in patients optimally treated with diuretics and ACE inhibitors, has a significantly greater beneficial effect on survival than metoprolol. The absolute reduction in mortality over 5 years was 5·7%. Survival times were consistent with a constant hazard in each group permitting estimation of median survival. Extrapolation from the survival curves suggested that carvedilol extended median survival by 1·4 years (95% CI 0·5-2·3) as compared with metoprolol (estimated median survival on carvedilol 8·0 years [95% CI 7·3-8·7], on metoprolol 6·6 years [6·1-7·1]). The calculated number of patient-years of treatment to save one life is 59, 23 which is similar to the effect of an ACE inhibitor or selective ␤-1 blocker versus placebo in comparable patient populations. The findings were consistent across predefined subgroups. Sensitivity analyses confirmed that the finding was robust and was not affected by variables such as the number of patients lost to follow-up or who withdrew consent. The patients included in the study had mild to severe heart failure (NYHA II-IV) and similar baseline characteristics to patients in earlier trials of ␤ blockers in heart failure. 5, 6 The yearly mortality rate was 8·3% for carvedilol and 10·0% for metoprolol. The yearly mortality rate in MERIT-HF 6 was 7·2% in the group given metoprolol, and in CIBIS-II 5 the rate was 8·8% in the group given bisoprolol.
The composite endpoint of all-cause mortality and allcause admission, although numerically in favour of carvedilol, was not significant. Withdrawals from the trial, excluding death, were almost identical. It is uncommon in clinical trials to find no significant treatment difference with respect to a composite endpoint, but a clear difference in one component such as mortality. 24 The benefit of carvedilol in this trial was thus driven by the reduction in mortality. The effect of carvedilol seems to be on a mechanism of death rather than on the determinants of admissions. The hazard reduction for cardiovascular mortality was 20%.
␤ blockers were first advocated for treatment of heart failure in 1975. 25 Results of large clinical trials subsequently showed that carvedilol, 4,7 metoprolol, 6 and bisoprolol 5 reduce mortality when added to conventional therapy. A trial with bucindolol 13 was not successful. The ␤ blockers proven to be effective differ by their adrenergic receptor selectivity and their ancillary properties. The results of our study together with those of other studies showing varying degrees of benefit and harm indicate that these differences are important for clinical outcomes.
Results of several small studies have shown favourable effects of carvedilol compared with metoprolol in terms of haemodynamics but similar effects on quality of life. 10, 12, [15] [16] [17] We began the trial in 1996 in response to the findings of earlier studies, 4, 26 but, during the course of the trial both of the drugs being compared had a favourable effect on mortality. In a large mortality study comparing two drugs, a decision has to be made about dose. The steering committee selected 25 mg twice daily for carvedilol and 50 mg twice daily for metoprolol to be used as target doses in COMET to achieve a comparable degree of ␤ blockade in both groups. 21 The evidence suggested that a dose ratio of 2 to 1 would achieve similar reductions in heart rate. In the Metoprolol Dilated Cardiomyopathy (MDC) trial 26 the target dose for metoprolol was 100-150 mg daily. The actual mean dose was 108 mg (SD 51) daily and the mean heart rate reduction was 15 beats per min. In the US carvedilol study 4 the mean daily dose was 45 mg (SD 27) and heart rate was reduced by 13 beats per min. The target dose of carvedilol in COPERNICUS 7 was 25 mg twice daily and the actual mean dose 37 mg daily.
In 1988, Sandberg and colleagues 27 compared a new multiple-unit, controlled release formulation of metoprolol, metoprolol succinate (metoprolol CR/XL), with the conventional metoprolol tartrate tablets in patients with heart failure and showed that the formulation showed a 30-35% reduced systemic availability. When COMET was started, this preparation was not available to us. The target dose used in MERIT-HF (200 mg metoprolol succinate) is equivalent to about 130 mg of the salt (metoprolol tartrate) used in COMET. In MERIT-HF the actual mean dose was 159 mg once daily (equivalent to 106 mg of metoprolol tartrate) and the reduction of heart rate 14 beats per min. In a post-hoc analysis of data from MERIT-HF 28 the risk reduction for mortality was identical in two groups analysed according to titrated dose (р100 mg daily, and >100 mg daily), which achieved mean doses of metoprolol succinate of 76 mg and 192 mg once daily, respectively. These doses are equivalent to 51 mg and 128 mg metoprolol tartrate, respectively. The on-treatment reductions of heart rate were 14 beats per min and 16 beats per min, respectively at 3 months. In COMET the mean doses at the onset of the maintenance phase were for carvedilol 42 mg daily and for metoprolol 85 mg daily. The respective reductions of heart rate from an on-treatment analysis were 13·3 beats per min and 11·7 beats per min. After 16 months there were no differences (figure 4). In CIBIS II 29 bisoprolol caused a mean reduction in heart rate of 10 beats per min at 2 months. The outcome of COMET is unlikely to be attributable to an effect of dose because of the comparability of the two doses as assessed from other studies, the flat dose-response to metoprolol in terms of heart rate and outcomes, 28 and the similar reduction of heart rate in the two groups. The small differences in the fall of heart rate in the first 16 months of the trial do not necessarily indicate a different degree of ␤ blockade. The antagonistic effect of carvedilol on ␤-2 and ␣-adrenergic receptors might have a discernible effect on heart rate and blood pressure. Clinical trials rarely establish a mechanism for any effect observed. The favourable outcome with carvedilol could be attributed to blockade of both ␤-1 and ␤-2 adrenergic receptors, inhibition of ␣-adrenergic receptors, a greater anti-ischaemic effect, inhibition of apoptosis, an antioxidant action, free radical scavenging, or an electrophysiological effect.
Three ␤ blockers have been shown to confer benefit on patients with chronic heart failure. Metoprolol and bisoprolol are selective ␤-1 adrenergic receptor inhibitors. No previous comparisons of ␤ blocking drugs with different properties on long-term mortality and morbidity have been made in patients with heart failure. The results of this study show that carvedilol extends survival by comparison with metoprolol in patients with chronic heart failure.
